SEC Form 8-K Summary
Registrant: Deep Medicine Acquisition Corp. (not TruGolf Holdings, Inc.)
Reporting date: September 6, 2022; filed September 12, 2022.
Business Context and Transaction
The filing reports an amendment to the previously announced Business Combination Agreement between Deep Medicine Acquisition Corp., Chijet Inc., Chijet Motor Company, Inc., Chijet Motor (USA) Company, Inc., Pubco, Merger Sub, and certain Chijet shareholders. The proposed transaction would result in Deep Medicine and Chijet becoming wholly owned subsidiaries of a newly formed holding company, Pubco.
Amendment No. 1 extends the due diligence period through September 20, 2022. The period is intended to allow Deep Medicine to complete its review of Chijet and its operations and determine a revised valuation. Deep Medicine is required to notify Chijet of the revised valuation by the end of the extended period.
Financial Metrics and Liquidity
This Form 8-K does not provide current or comparative revenue, profit, cash flow, margins, debt, liquidity, balance sheet, or operating-performance figures.
Material Changes Versus Prior Disclosure
- The due diligence period under the July 12, 2022 Business Combination Agreement was extended to September 20, 2022.
- All other provisions of the Business Combination Agreement remain in effect, subject to the amendment.
- The proposed transaction remained subject to further due diligence, valuation, regulatory and shareholder approval, and other closing conditions.
Outlook, Risks, and Unusual Items
The parties planned to file a Form F-4 registration statement containing a prospectus and proxy statement, but the filing states that the registration statement had not yet been filed with or declared effective by the SEC.
Key disclosed risks include failure to complete the transaction or obtain an extension of the business-combination deadline; excessive shareholder redemptions; failure to satisfy Nasdaq listing standards; failure to obtain shareholder approval or complete satisfactory due diligence; termination of the agreement; legal and regulatory issues; limited or inadequate financial information; Chijet’s early-stage operations; inability to recognize product revenue or secure contracts; execution, competition, market, economic, COVID-19, internal-control, and liquidity risks; and failure to realize anticipated transaction benefits.
The filing contains forward-looking statements regarding the proposed transaction, Chijet’s markets, future financial performance, valuation, ownership, liquidity, and expected benefits. These statements are subject to substantial uncertainty, and the parties disclaim an obligation to update them except as required by law.
Investor Verification Checklist
- Confirm the correct issuer: this filing identifies Deep Medicine Acquisition Corp., not TruGolf Holdings, Inc.
- Verify whether the extended due diligence period concluded on September 20, 2022 and what revised valuation was determined.
- Review the eventual Form F-4, proxy statement/prospectus, and subsequent SEC filings for transaction terms, financial statements, ownership, valuation, and closing conditions.
- Assess shareholder redemption levels, available cash, financing arrangements, and compliance with Nasdaq listing requirements.
- Review Chijet’s historical financial statements, revenue recognition, contracts, debt, liquidity, internal controls, and risk-factor disclosures.
- Confirm whether the Business Combination was completed, amended further, terminated, or otherwise affected by the stated conditions and risks.